Download PDF
Semin Thromb Hemost 2021; 47(04): 362-371
DOI: 10.1055/s-0041-1727284
Review Article

Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization

Matthias M. Engelen    *
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Christophe Vandenbriele   *
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Tim Balthazar
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Eveline Claeys
2   Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
,
Jan Gunst
3   Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
Ipek Guler
4   Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven, Belgium
,
Marc Jacquemin
5   Department of Cardiovascular Diseases and Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
,
Stefan Janssens
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Natalie Lorent
2   Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
,
Laurens Liesenborghs
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
6   The Outbreak Research Team, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
,
Kathelijne Peerlinck
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Griet Pieters
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Steffen Rex
7   Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium
8   Department of Cardiovascular Diseases, KU Leuven, Leuven, Belgium
,
Pieter Sinonquel
9   Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
,
Lorenz Van der Linden
10   Pharmacy Department, University Hospitals Leuven, Leuven, Belgium
11   Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
,
Christine Van Laer
12   Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
,
Robin Vos
13   Department of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium
,
Joost Wauters
14   Medical Intensive Care, University Hospitals Leuven, Leuven, Belgium
,
Alexander Wilmer
14   Medical Intensive Care, University Hospitals Leuven, Leuven, Belgium
,
Peter Verhamme
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
,
Thomas Vanassche
1   Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Venous thromboembolism (VTE) is a frequent complication of COVID-19, so that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with COVID-19 is well established. However, the incidence of VTE after discharge and whether postdischarge thromboprophylaxis is beneficial and safe are unclear. In this prospective observational single-center study, we report the incidence of VTE 6 weeks after hospitalization and the use of postdischarge thromboprophylaxis.

Methods Patients hospitalized with confirmed COVID-19 were invited to a multidisciplinary follow-up clinic 6 weeks after discharge. D-dimer and C-reactive protein were measured, and all patients were screened for deep vein thrombosis with venous duplex-ultrasound. Additionally, selected high-risk patients received computed tomography pulmonary angiogram or ventilation–perfusion (V/Q) scan to screen for incidental pulmonary embolism.

Results Of 485 consecutive patients hospitalized from March through June 2020, 146 patients were analyzed, of which 39% had been admitted to the intensive care unit (ICU). Postdischarge thromboprophylaxis was prescribed in 28% of patients, but was used more frequently after ICU stay (61%) and in patients with higher maximal D-dimer and C-reactive protein levels during hospitalization. Six weeks after discharge, elevated D-dimer values were present in 32% of ward and 42% of ICU patients. Only one asymptomatic deep vein thrombosis (0.7%) and one symptomatic pulmonary embolism (0.7%) were diagnosed with systematic screening. No bleedings were reported.

Conclusion In patients who had been hospitalized with COVID-19, systematic screening for VTE 6 weeks after discharge revealed a low incidence of VTE. A strategy of selectively providing postdischarge thromboprophylaxis in high-risk patients seems safe and potentially effective.

Keywords

venous thromboembolism - deep vein thrombosis - pulmonary embolism - COVID-19 - SARS-CoV-2 - anticoagulation - thromboprophylaxis after discharge - postdischarge thromboprophylaxis

* Contributed equally.




Publication History

Article published online:
23 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Published 2021. Updated February 5, 2021. Accessed February 5, 2021 at: https://covid19.who.int/
    Google Scholar
  • 2 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135 (23) 2033-2040
    CrossrefPubMedGoogle Scholar
  • 3 Fauvel C, Weizman O, Trimaille A. et al; Critical Covid-19 France Investigators. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J 2020; 41 (32) 3058-3068
    CrossrefPubMedGoogle Scholar
  • 4 Klok FA, Kruip MJHA, van der Meer NJM. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191: 148-150
    CrossrefPubMedGoogle Scholar
  • 5 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 6 Longchamp A, Longchamp J, Manzocchi-Besson S. et al. Venous thromboembolism in critically ill patients with COVID-19: results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost 2020; 4 (05) 842-847
    CrossrefPubMedGoogle Scholar
  • 7 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
    CrossrefPubMedGoogle Scholar
  • 8 Moll M, Zon RL, Sylvester KW. et al. VTE in ICU patients with COVID-19. Chest 2020; 158 (05) 2130-2135
    CrossrefPubMedGoogle Scholar
  • 9 Stessel B, Vanvuchelen C, Bruckers L. et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study. Thromb Res 2020; 194: 209-215
    CrossrefPubMedGoogle Scholar
  • 10 Bourguignon A, Beaulieu C, Belkaid W, Desilets A, Blais N. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thromb Res 2020; 196: 491-493
    CrossrefPubMedGoogle Scholar
  • 11 Kaptein FHJ, Stals MAM, Grootenboers M. et al; Dutch COVID & Thrombosis Coalition. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2020; 199: 143-148
    PubMedGoogle Scholar
  • 12 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
    CrossrefPubMedGoogle Scholar
  • 13 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 14 Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. JAMA 2020; 324 (08) 799-801
    CrossrefPubMedGoogle Scholar
  • 15 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost 2021; (epub ahead of publication) DOI: 10.1055/a-1347-6070.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. Thromb Haemost 2020; 120 (12) 1654-1667
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Patell R, Midha S, Kimani S. et al. Variability in institutional guidance for COVID-19-associated coagulopathy in the United States. Thromb Haemost 2020; 120 (12) 1725-1732
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Lynn L, Reyes JA, Hawkins K. et al. The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort. Thromb Res 2021; 197: 65-68
    CrossrefPubMedGoogle Scholar
  • 20 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Vandenbriele C, Van Aelst L, Balthazar T. et al. Anticoagulant therapy in COVID-19 critically ill: should we go for more?. J Kardiol 2020; 57 (05) 168-170
    PubMedGoogle Scholar
  • 22 Vanassche T, Orlando C, Vandenbosch K. et al. Belgian clinical guidance on anticoagulation management in hospitalised and ambulatory patients with COVID-19. Acta Clin Belg 2020; (e-pub ahead of print) DOI: 10.1080/17843286.2020.1829252.
    CrossrefPubMedGoogle Scholar
  • 23 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 24 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedGoogle Scholar
  • 25 Zayed Y, Kheiri B, Barbarawi M. et al. Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials. Intern Med J 2020; 50 (02) 192-199
    CrossrefPubMedGoogle Scholar
  • 26 Patell R, Bogue T, Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020; 136 (11) 1342-1346
    CrossrefPubMedGoogle Scholar
  • 27 Roberts LN, Whyte MB, Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136 (11) 1347-1350
    CrossrefPubMedGoogle Scholar
  • 28 Bellan M, Soddu D, Balbo PE. et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open 2021; 4 (01) e2036142
    CrossrefPubMedGoogle Scholar
  • 29 Chapman DG, Badal T, King GG, Thamrin C. Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients. Eur Respir J 2021; 57 (01) 2003263
    CrossrefPubMedGoogle Scholar
  • 30 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397 (10270): 220-232
    CrossrefPubMedGoogle Scholar